Search PubMed⌕ Search

Biomedical subjects

P Gabriele

Publications and source records attributed to P Gabriele.

At least 55 records · Page 3Linked to original sources
PubMed1990

[Thermal dose and fractionation in clinical hyperthermia].

Hyperthermia is one of the most promising methods for cancer treatment. Two important problems are nonetheless to be solved to define the actual role of this technique: the first one is how to express the thermal dose, and the second one is to assess the optimal sequence for the administration of heat and radiation. The authors critically reviewed the literature on the subject, pointing out those questions which have not yet been solved. Their work was then integrated with their own clinical experience on 191 lesions treated by hyperthermia alone or combined with radiotherapy. The impact is also analyzed of such prognostic factors as minimum intratumor temperature and total number of heating session on the final results.

Breast Neoplasms↗
PubMed1990

[Radiotherapy of carcinoma of the nasopharynx. Results and analysis of prognostic factors].

Radiation therapy of the patients with nasopharyngeal carcinoma results in permanent loco-regional control in 55-100% of cases according to stage of disease. Five-year overall survival rates range 30-55% and 5-year disease-free survival 30-40%. Factors affecting survival are: sex, age, overall patient conditions, Epstein-Barr associated antibodies, histology, T and N stages, cranial nerve and neck nodes involvement, staging method, dose and fractionation of radiation therapy, and adjuvant treatment. Our results in 94 patients can be summarized as follows: 78.4% local control, 89.8% control of lymph nodes clinically palpable at diagnosis, 40% overall 5-year survival, and 38% 5-year disease-free survival. Significant prognostic factors in our series of patients were T and N stages and histology.

Adult↗
PubMed1990

[5- and 10-year survival in carcinomas of the oral cavity (T1-2/N0-1) treated with external radiotherapy alone or associated with surgery and/or chemotherapy].

The authors report their results on the treatment of 211 T1-2/N0-1 carcinoma of the oral cavity treated with radiotherapy alone or associated with surgery and/or chemotherapy. Five- and ten-year survival rates are respectively 48 and 37%. Two groups were recognized: one with a better prognosis (T1 gum and cheek) and another with a poor prognosis (T2-N1 mobile tongue and floor of the mouth).

Adult↗
PubMed1989

Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.

Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen. Previous therapy included surgery (1 case), radiotherapy (1 case), and surgery + radiotherapy (7 cases). There was 1 complete response (11.1%), 3 partial responses (33.3%), 2 unchanged lesions (22.2%) and 3 progressions (33.3%). Patients with local recurrence had a better response. Median remission duration was 7.5 months in CR + PR patients. Median overall survival was 8+ months; 14+ months for responders and 4 months for nonresponders. The major toxic effects were nausea/vomiting and alopecia; myelosuppression was less frequent and usually not severe.

Adenocarcinoma↗
PubMed1989

Results of hyperthermia, alone or combined with irradiation, in chest wall recurrences of breast cancer.

In the period between September 1983 and July 1987, 28 locoregional recurrences (about 86% in the chest wall) of breast cancer in 19 patients were treated with external microwave hyperthermia. Of these, 11 lesions were treated with hyperthermia alone and 17 with the combination of heat and external irradiation. Hyperthermia was induced in most cases with 915 MHz microwave (at least 42 degrees C for 30-45 min, for 6-10 sessions). Radiation was administered using photon or electron beams with total doses varying from 2000 to 5000 cGy. Complete and partial response rates on the whole series of patients were 53.6% and 42.9%, respectively. Of 17 lesions treated with combined treatment, 10 had a complete (58.8%) and 7 a partial response; of 11 lesions treated with hyperthermia alone, 5 had a complete (45.5%), 5 a partial (45.5%), and 1 no response. Complete responses were long lasting in all but 3 cases, which recurred after 4 months (2 cases) and 1 year, respectively.

Adult↗
PubMed1989

Combined chemotherapy for recurrent and metastatic nasopharyngeal carcinoma.

Thirty-two patients (24 males, 8 females; median age 54 yrs) with recurrent and/or metastatic undifferentiated carcinoma of the nasopharyngeal type were treated with chemotherapy. Remissions were observed in 17 of 32 (53.2%) with 5 complete (CR) (15.6%) and 12 partial responses (PR) (37.6%). A combination of cisplatin and 5-fluorouracil was the most effective regimen (CR + PR = 83.3%). Objective responses. (CR + PR) were 47% (CR = 11.7%) in schemes without cisplatin and 60% (CR = 20%) in cisplatin-based combinations. The median overall duration of response was 7.2 months. The median overall survival time was 10.3 months: 15.1 months for responders and 5.2 for non-responders. No important toxicity was observed.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

Clinical hyperthermia, alone or with radiation therapy: results of a preliminary study on recurrences of cancers.

Authors present results obtained by hyperthermic treatment (alone or associated with radiation therapy) on 50 patients (with a total of 66 sites) treated between September 1983 and August 1986. All patients had recurrent or metastatic lesions of pretreated malignant tumors. Among these there were 19 breast adenocarcinomas, 33 squamous cell carcinomas of head and neck, 9 melanomas and 5 subcutaneous metastases of adenocarcinoma of the cervix, rectum and colon. The clinical protocol was: hyperthermia alone (43 degrees -45 degrees C for 30 minutes, bi-weekly, for 4-5 weeks) or hyperthermia plus radiation therapy (4 Gy/fraction) for a total of 8-10 seances, in accordance with previous given doses of irradiation. In summary, complete response rates were 21.2% for head and neck tumors, and 51.5% for cutaneous or subcutaneous lesions. Results have also been analysed according to different prognostic variables related to tumor and treatment characteristics. These data are discussed.

Adenocarcinoma↗
PubMed1989

Three new applicators for hyperthermia.

A computerized system with automatic treatment parameters control for radiological hyperthermia, called Sapic SV03, is presented. The system has been planned and built by the "Sezione Avionica ed Equipaggiamenti" of the Aeritalia in cooperation with the Radiotherapy Department of the University of Turin. The device is supplied with a multifrequency generator system (915, 433, 2-30 MHz) connected with many kinds of applicators, with a fiber optic system for temperature control and a previsional thermometry system. In this paper the authors presented three new applicators. The first one is a concave parallel microstrip applicator at 433 MHz, with a size 16 x 9 cm; the heating pattern is homogenous until 4 cm of depth. This antenna can be used for the treatment of chest wall recurrences of breast cancer. The second is a 27 MHz inductive ring and the third applicator is a pyramidal antenna ("TEM line") that operates at a frequency around 27 MHz.

Computer Systems↗
PubMed1988

[Radiotherapy in the treatment of carcinoma of the major salivary glands].

The authors conducted a retrospective study on 99 patients with malignant tumors of the major salivary glands, who had been treated by radiotherapy between 1976 and 1986: 86 cases of parotid tumors and 13 cases of submandibular gland tumors. Only 28 tumors (28%) were T1-T2, N0-N1. Local control, 3-5 and 8-year survival rates, and complications were considered. Radiation therapy alone was performed on 19 patients (19%), while combined surgical and radiation therapy was performed on 80 patients (80%). The results of radiation therapy alone and combined with surgery are discussed. Loco-regional disease control was obtained in 9 out of 19 patients (47%) by irradiation alone, and by combined irradiation and surgery in 60 out of 80 cases (75%). Distant metastases developed in 23 out of 99 patients (23%). Loco-regional metastases were the most frequent cause of death (20 out of 55 cases: 36%). Severe complications were extremely rare. The results demonstrate not only the advantages of combined treatment but also the value of radiotherapy alone in the treatment of tumors of the major salivary glands.

Adolescent↗
PubMed1988

[Radiotherapy in the treatment of carcinomas of the base of the tongue. Analysis of the literature and personal experience].

Carcinoma of the base of the tongue is usually treated with radiation therapy. After a review of the literature, the findings are reported of 129 patients with squamous cell carcinoma of the base of the tongue treated in 1979-1983, with a minimum of a 3-year follow-up: 8 T1, 40 T2, 60 T3 and 21 T4 were found; only 48 cases were N0. Advanced stages (stage III and stage IV) were 83% of the total. External photon irradiation (Cobalt-60) was used in all cases; 33 patients underwent chemotherapy or surgery as additional treatment. The overall local control rate was 45.7%. Local control decreased as T stage advanced: T1 62.5%, T2 55%, T3 41.7% and T4 33.3%. The overall regional control rate for lymph nodes clinically palpable was 51.8%. The overall actuarial 5-year survival rate was 29.1%. The 5-year survival rate according to the N-staging varied from 37% for N0-stage to 17.4% for N3-stage. The majority of failures (92.8%) occurred within 2 years since the end of the therapy. Treatment complications, secondary carcinomas and causes of death are also discussed. Radiation therapy has proven to be effective for early-stage carcinoma of the base of the tongue; in more extensive lesions results are poor. Improved results could be obtained by optimal application of radiotherapeutic techniques. Knowledge of the various prognostic factors is essential to administer the therapeutic regimen for a given patient by the characteristics of his particular tumor.

Adult↗
PubMed1988

Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.

Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with an outpatient schedule: cisplatin (100 mg/m2) day 1 and an 8-hour infusion of 5-fluorouracil (1000 mg/m2) on days 1-4 every 28 days. Twenty-eight patients were evaluable for response and toxicity: there were 5 complete responses (17.8%), 12 partial responses (42.8%), 6 stable disease (21.6%) and 5 progressions (17.8%). Patients with good performance status had a better response; patients who received prior chemotherapy had less positive responses. Median remission duration was 30+ weeks in patients who had a complete response, 25+ weeks in patients with a partial response. Median overall survival was 28+ weeks: 36+ weeks for responders and 14 weeks for non-responders. The major toxic effect was nausea/vomiting, while myelosuppression and stomatitis were less frequent and never severe.

Adult↗
PubMed1987

Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.

Forty-eight fully assessable previously treated patients with biopsy-proven recurrent squamous cell carcinoma of the oral cavity were randomized to receive either methotrexate (MTX), 40 mg/m2 iv push weekly, or sequential MTX and 5-fluorouracil (5-FU) (MTX 150 mg/m2 iv for 1 h; 1 h after the end of MTX, 5-FU 600 mg/m2 iv for 2 h; 24 h later, leucovorin rescue 10 mg/m2 iv and the same dose was given orally every 6 h 4 times; the treatment was repeated every 10 days). There were 1 complete response (CR) and 5 partial responses (PR) in the MTX group; median remission duration = 84 days. There were 3 CR and 11 PR in the MTX-5-FU group (overall response 14/24, 58.3%--p less than 0.05); median remission duration = 125 days. Median survival was 6.2 months in the MTX group and 8.1 months in the MTX-5-FU group. There was no difference in mucositis between the two groups, and a prevalence of leukopenia and moderate gastro-intestinal toxicity in the MTX-5-FU group.

Adult↗
PubMed1987

[Results of radiotherapy in the treatment of 218 carcinomas of the tonsillar area].

After a brief review of the literature, the results of the treatment by radiation therapy in 218 patients with tonsillar region carcinoma are reported. The patients were treated at the Turin University Radiotherapy Department (131 cases) and at the Radiotherapy Department of the Ospedale Maggiore, Novara (87 cases) from 1976 through 1984. The series included 29 T1, 88 T2, 64 T3 and 37 T4; 86 patients (40%) were N0. Only 49 patients were stages I and II (1/4 of the total). The local control (T) rate at the end of therapy was 63.5% for the overall series (139/218) ranging from 100% in T1, 72.6% T2, 54.6% T3 to 30% T4; the regional control (N) for patients with cervical lymphadenopathy was 66% (88/132). The overall 5-year survival was 38%; the 5-year disease-free survival was 35%. The 5-year survival according to T-stage was 52% for limited cases (T1-T2) in comparison to 22% for advanced ones (T3-T4). The 5-year survival for N0 stage was 55%; when neck nodes were present (N # 0) the survival was 29% after 5 years. Complications included 6 cases of trismus and 2 osteonecroses of the mandible. Second primary malignant diseases were seen in 17 cases (7.8%). The most common cause of death was failure in primary tumour control (80% of cases). In this series the results of radiotherapy of early stage tonsillar carcinomas are quite good; patients with large tumour masses fare less satisfactorily. Better results should be obtained in the future by identifying prognostic factors, monitoring potential causes of treatment failure and optimizing the radiotherapeutic treatment plan and technique.

Adult↗
PubMed1986

[Carcinoma of the paranasal sinuses. Results with radiotherapy alone or with a radio-surgical combination].

The authors evaluate 117 patients affected by paranasal sinuses carcinoma treated by radiation therapy alone or by post-operative irradiation, from 1976 to 1984. Among these: 4 T1, 21 T2, 48 T3 and 44 T4; 66 cases were squamous cell carcinomas, 23 adenocarcinomas, 16 undifferentiated carcinomas and 12 adenoid cystic carcinomas. The overall 3 and 5 years actuarial survival rates were, respectively, 46% and 27%. The survival rates for stages T1 and T2 were 82 and 48% at 3 and 5 years; for stages T3 and T4 were 36% and 21%. According to the hystological type the survival rate varied from 50% for adenoid cystic carcinomas to 0% for undifferentiated carcinomas at 5 years. The survival rate for the group of patients treated with post-operative irradiation was 37% at 5 years, versus 10% for the group treated by radiotherapy alone. Complications have been minimal. Causes of failure are discussed. In conclusion, the authors consider a multicentric study as necessary to determine the efficacy of various schedules of treatment.

Adult↗